The investigational drug, Trastuzumab Emtansine (T-DM1), improves survival of patients with HER2-Positive metastatic breast cancer "significantly", Genentech Inc. announced today as it published highlights of its Phase III EMILIA study results. T-DM1 was compared to lapatinib and Xeloda (capecitabine) combination therapy...
More...